180 related articles for article (PubMed ID: 29557709)
1. Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans.
Kogame A; Lee R; Pan L; Sudo M; Nonaka M; Moriya Y; Higuchi T; Tagawa Y
Xenobiotica; 2019 Apr; 49(4):433-445. PubMed ID: 29557709
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Fasiglifam-Related Liver Toxicity in Dogs.
Kogame A; Moriya Y; Mori I; Pan L; Morohashi A; Ebihara T; Fukui H; Tagawa Y; Benet LZ
Drug Metab Dispos; 2019 May; 47(5):525-534. PubMed ID: 30765394
[TBL] [Abstract][Full Text] [Related]
3. Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs.
Kogame A; Takeuchi T; Nonaka M; Yamasaki H; Kawaguchi N; Bernards A; Tagawa Y; Morohashi A; Kondo T; Moriwaki T; Asahi S
Xenobiotica; 2017 Mar; 47(3):255-266. PubMed ID: 27225050
[TBL] [Abstract][Full Text] [Related]
4. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
Li X; Zhong K; Guo Z; Zhong D; Chen X
Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
[TBL] [Abstract][Full Text] [Related]
5. Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury.
Wolenski FS; Zhu AZX; Johnson M; Yu S; Moriya Y; Ebihara T; Csizmadia V; Grieves J; Paton M; Liao M; Gemski C; Pan L; Vakilynejad M; Dragan YP; Chowdhury SK; Kirby PJ
Toxicol Sci; 2017 May; 157(1):50-61. PubMed ID: 28108665
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo metabolic profiles of fasiglifam using ultrahigh-performance liquid chromatography combined with Q-Exactive Orbitrap tandem mass spectrometry.
Li JQ; Li J; Wang JF; Zhang SH; He D; Yong RS; She SY
Rapid Commun Mass Spectrom; 2018 Aug; 32(16):1387-1395. PubMed ID: 29790616
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the pharmacokinetics and metabolic fate of Fasiglifam (TAK-875) in male and female rats following oral and intravenous administration.
Molloy BJ; King A; Gethings LA; Plumb RS; Mortishire-Smith RJ; Wilson ID
Xenobiotica; 2023 Feb; 53(2):93-105. PubMed ID: 36794569
[TBL] [Abstract][Full Text] [Related]
8. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats.
Murai T; Takakusa H; Nakai D; Kamiyama E; Taira T; Kimura T; Jimbo T; Bathala M; Pickersgill F; Zahir H; Tokui T; Savage RE; Ashwell MA; Izumi T
Xenobiotica; 2014 Nov; 44(11):996-1008. PubMed ID: 24911380
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans.
Atsriku C; Hoffmann M; Ye Y; Kumar G; Surapaneni S
Xenobiotica; 2015 May; 45(5):428-41. PubMed ID: 25482583
[TBL] [Abstract][Full Text] [Related]
11. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment.
Marcinak J; Vakilynejad M; Kogame A; Tagawa Y
Drugs R D; 2018 Jun; 18(2):109-118. PubMed ID: 29488154
[TBL] [Abstract][Full Text] [Related]
13. Fasiglifam as a new potential treatment option for patients with type 2 diabetes.
Kaku K
Expert Opin Pharmacother; 2013 Dec; 14(18):2591-600. PubMed ID: 24195772
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic investigations of the liver toxicity of the free fatty acid receptor 1 agonist fasiglifam (TAK875) and its primary metabolites.
Ackerson T; Amberg A; Atzrodt J; Arabeyre C; Defossa E; Dorau M; Dudda A; Dwyer J; Holla W; Kissner T; Kohlmann M; Kürzel U; Pánczél J; Rajanna S; Riedel J; Schmidt F; Wäse K; Weitz D; Derdau V
J Biochem Mol Toxicol; 2019 Aug; 33(8):e22345. PubMed ID: 31066974
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of TAK-475, a Squalene Synthase Inhibitor, in Rats and Dogs.
Ebihara T; Teshima K; Kondo T; Tagawa Y; Moriwaki T; Asahi S
Drug Res (Stuttg); 2016 Jun; 66(6):287-92. PubMed ID: 26839207
[TBL] [Abstract][Full Text] [Related]
17. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
18. Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.
Otieno MA; Snoeys J; Lam W; Ghosh A; Player MR; Pocai A; Salter R; Simic D; Skaggs H; Singh B; Lim HK
Toxicol Sci; 2018 Jun; 163(2):374-384. PubMed ID: 28206647
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
[TBL] [Abstract][Full Text] [Related]
20. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
